Study reveals impact of viral combinations on infant respiratory illness severity

A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral combinations dramatically increase the risk of severe disease. The findings, published this month in Journal of Infection, come from the Puerto Rican Infant Metagenomic and Epidemiologic Study of Respiratory Outcomes (PRIMERO), which followed more than 2,000 children from birth to age two between 2020 and 2024.

The research, led by Max A. Seibold, PhD, and his team at National Jewish Health, is one of the most detailed examinations to date of how multiple viral species interact in early life to influence respiratory illness severity and potential future asthma risk.

We found that whether upper respiratory tract infections in early-life result in lower airway symptoms is strongly related to the virus involved. While viruses like RSV and metapneumovirus inherently carry a high risk of severe lower airway infection, others such as rhinovirus and bocavirus are much more likely to be dangerous when they are present together or in combination with other viruses."

Dr. Max A. Seibold, PhD, director of the Regenerative Medicine and Genome Editing Program (REGEN) at National Jewish Health

These insights help us better understand why some early-life viral infections cause relatively minor colds, while other infections result in severe respiratory illnesses.

The study found that respiratory syncytial virus (RSV) infections conferred the highest risk of severe lower respiratory illness in infants, increasing the odds of serious illnesses nearly ninefold. Other viruses such as metapneumovirus, parainfluenza, and common coronaviruses were also linked to higher risk of severe disease. In contrast, rhinovirus and bocavirus, despite being the most frequently detected viruses in severe illnesses, were just as likely to cause a mild cold as a severe illness. However, the risk associated with these viruses increased when infants were infected with both rhinovirus and bocavirus at the same time. Specifically, co-infection with rhinovirus and bocavirus nearly tripled the odds of developing a severe lower respiratory infection compared to being infected with just one of the viruses. Interestingly, SARS-CoV-2 infections were associated with a lower risk of severe illness in infants, suggesting that young children may have unique immune responses that protect them from the more serious outcomes often seen in adults.

Researchers say the findings underscore the importance of comprehensive viral surveillance and targeted prevention strategies, especially for high-risk populations such as Puerto Rican infants, who experience disproportionate rates of asthma and respiratory disease.

Understanding which viruses or viral combinations lead to the most severe outcomes can inform early interventions. This includes vaccination strategies and better clinical monitoring for infants with co-infections."

Camille Moore, PhD, study's lead author

Source:
Journal reference:

Moore, C. M., et al. (2025). Independent and interactive effects of viral species on early-life lower respiratory tract illness. Journal of Infection. doi.org/10.1016/j.jinf.2025.106616

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bedfont® to showcase the innovative Smokerlyzer® and NObreath® respiratory devices at ERS 2025